MANGOCEUTICALS, INC. 8-K

What Happened
Mangoceuticals, Inc. (MGRX) said on its Form 8-K filed Feb. 6, 2026 that on Feb. 4, 2026 it received a deficiency notice from the Nasdaq Listing Qualifications Staff. Nasdaq notified the company it is not in compliance with Nasdaq Listing Rule 5550(a)(2) because the bid price of its common stock closed below $1.00 per share for 30 consecutive business days. Nasdaq’s notice does not currently affect the listing or trading of the stock.

Key Details

• Nasdaq notice date: February 4, 2026; Form 8-K filed February 6, 2026.
• Rule cited: Nasdaq Listing Rule 5550(a)(2) — minimum $1.00 bid price requirement.
• Cure period: 180 calendar days from the notice (until August 3, 2026).
• To regain compliance the stock must close at $1.00 or more for at least 10 consecutive business days.
• Company statement: it will monitor the closing bid and “consider available options” to resolve the deficiency.

Why It Matters
A failure to meet Nasdaq’s minimum bid-price rule can ultimately lead to delisting, which would reduce liquidity and make the shares harder to trade. However, Mangoceuticals has a defined cure period and the notice does not stop current trading. Retail investors should monitor the company’s stock price and any further filings or announcements about steps the company may take to regain compliance.